Saga Diagnostics completed a $4.2M investment round from Hadean Ventures and existing investors.
Saga Diagnostics AB, a Lund, Sweden-based medical company focused on ultrasensitive monitoring of cancer patients using blood samples and other liquid biopsies and tissues, announced that it completed a SEK 40M ($4.2M) capital investment round.
In conjunction with the funding, Walter Stockinger, managing partner of Hadean Ventures, joined Saga’s board.
Funding will be used to accelerate commercialization of Saga’s portfolio of kits and services, continue development of new products, and perform prospective clinical studies. In addition, regulatory activities towards laboratory ISO accreditation and the first CE-IVD marked kits are underway.
Saga Diagnostics, led by CEO Lao Saal, is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. Saga helps pharmaceutical companies, scientists, and biomedical laboratory providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, ultimately giving patients peace of mind.